Masan’s masterplan to lure investors

Masan’s masterplan to lure investors

The establishment of The CrownX opens the first chapter of Masan’s Point of Life strategy, which aims to serve essential products and services on an integrated offline-to-online platform.
Stable figures for M&A as groups rebuild

Stable figures for M&A as groups rebuild

Dealmaking in Vietnam is showing signs of recovery after a subdued year, and domestic figures are even surpassing pre-pandemic levels.
SK Group to spend $340 million to increase stake in Masan's retail arm

SK Group to spend $340 million to increase stake in Masan's retail arm

SK Group will spend $340 million acquiring shares of The CrownX (TCX) under Masan Group to double down on the latter's Point of Life (POL) strategy.
International investors scoop up major stakes in drugmakers

International investors scoop up major stakes in drugmakers

Dealmaking and investment in pharmaceutical and healthcare businesses are increasing in scope as investors are vying for the controlling stake of key players.
SK Group donates $1 million to Vietnam’s vaccine fund

SK Group donates $1 million to Vietnam’s vaccine fund

SK Group donated $1 million for Vietnam’s COVID-19 Vaccine Fund in order to support the procurement, vaccination, R&D, and production of domestic vaccines.
Foreign investors maintain interest in Vietnam

Foreign investors maintain interest in Vietnam

Despite a year-on-year slip in foreign direct investment (FDI) to Vietnam in the first four months of the year, foreign investors still signed major deals in the country and confirmed its ongoing investment appeal.
Hydrogen fuel cell maker Plug Power to expand operations with SK Group

Hydrogen fuel cell maker Plug Power to expand operations with SK Group

Plug Power is signalling interest in potential markets, including Vietnam, South Korea, and China through a joint venture with SK Group.
South Korean investors back from recess

South Korean investors back from recess

The South Korean investment landscape in Vietnam is brightening up, following new investments worth billions of dollars, with SK and Hanwha pouring a great deal into their projects.
M&A on cusp of post-COVID-19 surge

M&A on cusp of post-COVID-19 surge

As global mergers and acquisitions activity continues to rebound following a pandemic-fuelled freeze, Vietnam is expected to benefit from the growth of deal-making.
Robust growth trends projected for investment in healthcare

Robust growth trends projected for investment in healthcare

Vietnam’s healthcare and pharmacy chains are increasingly getting new funds to expand their operations in local market, thereby securing access and availability of medical supplies and drugs for locals. However, concerns over adequate human resources in the sector dampen the bright prospects and could cause supply issues.
SK Group to acquire 16.26 per cent stake in VinCommerce

SK Group to acquire 16.26 per cent stake in VinCommerce

SK Group will acquire a 16.26 per cent stake in VinCommerce for a total cash consideration of $410 million.
New M&As in healthcare can evade pandemic uncertainties

New M&As in healthcare can evade pandemic uncertainties

Mergers and acquisitions in Vietnam’s healthcare and pharmaceutical sector in 2020 have been held up due to the global health crisis – but prospects remaining enticing thanks to new drivers of interest.
South Koreans grow presence through substantial M&A

South Koreans grow presence through substantial M&A

South Korean investors are employing mergers and acquisitions as a critical strategic instrument to secure a stronger footing in Vietnam.
M&A set for a bustling second half

M&A set for a bustling second half

M&A deal-making will probably increase at a steady pace in the second half of 2020, led by the upcoming mega deal of Vietnam’s leading brewer Sabeco.
SK Group expands pharma foothold

SK Group expands pharma foothold

With SK Group recently joining the mergers and acquisitions race, Vietnam’s pharma and healthcare market is becoming more robust. However, newcomers are expected to face challenges amid increasingly mounting competition in the lucrative pharmaceutical market in the months to come, driven by the enforcement of the EU-Vietnam Free Trade Agreement.
1 2 3